不同抗骨质疏松药物对骨折后死亡率影响的比较:一项基于人群的研究
该研究利用台湾地区2009至2017年医保数据库的纵向人群数据,纳入46729例≥40岁骨质疏松性骨折并使用抗骨质疏松药物的患者,随访至2018年。多变量Cox模型显示,与雷洛昔芬和巴多昔芬相比,阿仑膦酸/利塞膦酸(HR 0.83;95%CI 0.79-0.88)、地舒单抗(HR 0.86;95%CI 0.81-0.91)和唑来膦酸(HR 0.78;95%CI 0.73-0.84)的全因死亡率显著更低,且长期作用的唑来膦酸在性别或年龄>65岁亚组中死亡率最低。结论提示抗骨质疏松药物尤其是长效方案可能降低骨折后死亡率。
要点
- 阿仑膦酸/利塞膦酸、地舒单抗和唑来膦酸较雷洛昔芬/巴多昔芬显著降低骨折后全因死亡率。
- 唑来膦酸在总骨折组中HR 0.78;95%CI 0.73-0.84,为所比较药物中死亡率最低。
- 按照性别或年龄>65岁亚组分析,接受长效唑来膦酸者死亡率最低。
核心结论
- 这项真实世界大数据研究提示,使用抗骨质疏松药物尤其是长效方案可能降低骨折后死亡率。
研究设计与样本
- 纵向基于人群的骨折后队列研究,使用台湾地区全民健康保险研究数据库2009至2017年数据,纳入≥40岁骨质疏松性骨折并使用抗骨质疏松药物的个体,随访至2018年。
- 共纳入46729例受试者,平均年龄74.45岁(女性80.0%),平均随访4.73年。
- 采用多变量Cox比例风险模型评估骨折部位与死亡率的关系,并按抗骨质疏松药物分层,同时处理不朽时间偏倚。
主要发现
- 在总骨折组中,与雷洛昔芬和巴多昔芬相比,阿仑膦酸/利塞膦酸(HR 0.83;95%CI 0.79-0.88)、地舒单抗(HR 0.86;95%CI 0.81-0.91)和唑来膦酸(HR 0.78;95%CI 0.73-0.84)的死亡率显著更低。
- 在髋部骨折、椎体骨折或非髋部/非椎体骨折组中观察到相似趋势。
- 按照性别或年龄>65岁亚组分析,接受长效唑来膦酸者死亡率最低。
关键数值与推荐
- 总骨折组中,与雷洛昔芬和巴多昔芬相比,阿仑膦酸/利塞膦酸的HR为0.83(95%CI 0.79-0.88)。
- 总骨折组中,与雷洛昔芬和巴多昔芬相比,地舒单抗的HR为0.86(95%CI 0.81-0.91)。
- 总骨折组中,与雷洛昔芬和巴多昔芬相比,唑来膦酸的HR为0.78(95%CI 0.73-0.84)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Osteoporosis is becoming a global epidemic in aging societies. Anti-osteoporotic medications can prevent fractures, and their pleiotropic effect on mortality is interesting but not well compared among each other. OBJECTIVE: To provide real-world evidence on the pleiotropic effect of different anti-osteoporotic medications on all-cause mortality, stratified by fracture site, sex, and age. METHODS: This longitudinal population-based postfracture cohort study, included mega-data from subjects ≥40 years of age with osteoporotic fracture who used anti-osteoporotic medications as recorded in Taiwan's National Health Insurance Research Database from 2009 to 2017 and followed until 2018. A multivariate Cox proportional hazards model with immortal time bias was used to assess the relationship between fracture sites and mortality stratified by anti-osteoporosis medication. RESULTS: A total of 46 729 subjects with an average age of 74.45 years (80.0% female) and a mean follow-up period of 4.73 years were enrolled. In the total fracture group, compared with raloxifene and bazedoxifene, we found that alendronate/risedronate (hazard ratio [HR] 0.83; 95% CI, 0.79-0.88), denosumab (HR 0.86; 95% CI, 0.81-0.91), and zoledronic acid (HR 0.78; 95% CI, 0.73-0.84) resulted in significantly lower mortality. Similar trends were observed in the hip, vertebral, or nonhip/nonvertebral fracture groups. Subjects receiving long-acting zoledronic acid showed the lowest mortality in the subanalysis according to sex or age over 65 years. CONCLUSION: This real-world mega-data study suggests that the usage of osteoporotic medication, especially a long-acting regimen, may lower postfracture mortality.
引用
- Wu CH, Li CC, Hsu YH, et al. Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study. J Clin Endocrinol Metab. 2023. PMID: 36317591. doi:10.1210/clinem/dgac636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。